News and Trends 18 Jul 2022 Enterome and Nestlé Health Science to work on food allergies and inflammatory bowel disease Enterome, a clinical stage biopharmaceutical company developing immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, has signed a strategic R&D collaboration and license agreement with Nestlé Health Science targeting food allergies and inflammatory bowel disease (IBD). The collaboration aims to develop and commercialize Enterome’s lead EndoMimics pipeline candidate EB1010. EB1010 is a local […] July 18, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022Beyond Biotech podcast 5: ANeuroTech, ISA Pharmaceuticals, Life Length This week’s guests are Erik Buntinx, CEO and founder of ANeuroTech; Stephen J. Matlin, CEO of Life Length; and Kees Melief, chief scientific officer at ISA Pharmaceuticals. ISA Pharmaceuticals’ clinical trial using AMPLIVANT technology A clinical trial using ISA Pharmaceuticals’ AMPLIVANT adjuvant technology started in April. The trial, run by partner Scancell Holdings plc is […] July 14, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Telo Genomics launches clinical study of drug resistance test for multiple myeloma Canadian biotech company Telo Genomics Corp. has started the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma (MM) patients at high-risk of developing treatment resistance. The study is the second being carried out in collaboration with the Mayo Clinic to evaluate the company’s prognostic technology to address multiple unmet clinical […] July 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Orthox green light for knee cartilage repair clinical trial Orthox Limited, a clinical stage company developing medical implants to repair damaged knee articular cartilage and other orthopaedic injuries, can start its FFLEX (FibroFix cartilage repair experience) study. The company has received a Letter of No Objection from the UK’s MHRA, enabling the start of the study. The study, which is also supported by funding […] July 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Report says tech talent is hard to find Randstad Sourceright’s 2022 life sciences and pharma Talent Trends report finds a third of C-suite and human capital leaders in the life sciences and pharmaceuticals sector say talent scarcity is a major pain point for the sector, which is hiring extensively this year. With demand for life sciences products expected to grow faster than the […] July 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 Endogena Therapeutics to start clinical stage with treatment for blindness caused by retinitis pigmentosa Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for […] July 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 Biotech food colorant startup Phytolon seals $14.5M in funding Phytolon, a developer of fermentation-based natural food colors, has secured $14.5 million in funding, led by DSM Venturing, to further progress its technology towards commercialization. Other participation came from Cibus Fund, Ginkgo Bioworks (in-kind investment in the form of Foundry services) and The Trendlines Agrifood Fund. Participation in the series A funding also includes some […] July 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 8 Jul 2022Beyond Biotech podcast 4: CorePath, Rensselaer, Versameb This week’s guests are: Helen Zha, assistant professor of chemical and biological engineering and a member of the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic Institute; Versameb CEO Klaas Zuideveld; and Aamir Ehsan, CEO and medical director of CorePath and Celina Villa, medical director of Biopharma Division. Versameb gives presentation during World […] July 8, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Destiny Pharma announces start of new oral mucositis research program Oral mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2 million cancer patients every year. Destiny Pharma plc, a clinical-stage biotech company focused on the development of novel medicines that can prevent life-threatening infections, has started a new research program on the condition. The research study will be […] July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS EditForce, Inc. has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to research, develop and commercialize potential gene therapy products for a specific target disease related to the central nervous system (CNS) by utilizing EditForce’s pentatricopeptide repeat (PPR) protein platform technology. MTPC and EditForce aim to create potential novel pharmaceuticals for the […] July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Novartis Pharmaceuticals UK launches health-tech investor partnership for cardiovascular care Novartis Pharmaceuticals UK has launched the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. The initiative aims to identify and implement solutions that empower patients to improve their heart health, and to […] July 5, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Mogrify and Astellas to address sensorineural hearing loss Biopharma company Mogrify Limited, and Japanese regenerative medicine firm Astellas Pharma Inc., have announced a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss. Utilizing Mogrify’s direct cellular reprogramming platform, the collaboration will seek to identify novel combinations of transcription factors involved in cell differentiation to generate new cochlear hair […] July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email